Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,986 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S. Iwamoto T, et al. Breast Cancer Res Treat. 2024 Jan;203(2):225-234. doi: 10.1007/s10549-023-07144-2. Epub 2023 Oct 25. Breast Cancer Res Treat. 2024. PMID: 37875670
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Iwamoto T, et al. Breast Cancer Res Treat. 2011 Feb;125(3):785-95. doi: 10.1007/s10549-010-1280-6. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153052 Free PMC article.
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Hayashi N, et al. Among authors: iwamoto t. Oncologist. 2011;16(7):956-65. doi: 10.1634/theoncologist.2010-0409. Epub 2011 Jun 28. Oncologist. 2011. PMID: 21712485 Free PMC article.
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S, Higaki K, Fujiwara T, Doihara H, Symmans WF, Pusztai L. Itoh M, et al. Among authors: iwamoto t. Breast Cancer Res Treat. 2014 Jan;143(2):403-9. doi: 10.1007/s10549-013-2763-z. Epub 2013 Dec 15. Breast Cancer Res Treat. 2014. PMID: 24337596 Free article.
Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, Iwamoto T, Oshitanai R, Morioka T, Tuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y. Niikura N, et al. Among authors: iwamoto t. Clin Breast Cancer. 2014 Oct;14(5):323-329.e3. doi: 10.1016/j.clbc.2013.12.013. Epub 2013 Dec 30. Clin Breast Cancer. 2014. PMID: 24492237
Assessment of the Ki67 labeling index: a Japanese validation ring study.
Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N, Yoshida K, Kadoya T, Tamaki K, Kumaki N, Iwamoto T, Sugie T, Moriya T. Niikura N, et al. Among authors: iwamoto t. Breast Cancer. 2016 Jan;23(1):92-100. doi: 10.1007/s12282-014-0536-0. Epub 2014 May 3. Breast Cancer. 2016. PMID: 24794952
Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
Niikura N, Hashimoto J, Kazama T, Koizumi J, Ogiya R, Terao M, Oshitanai R, Morioka T, Tsuda B, Okamura T, Saito Y, Iwaisako K, Iwamoto T, Hayashi N, Imai Y, Tokuda Y. Niikura N, et al. Among authors: iwamoto t. Breast Cancer. 2016 Jul;23(4):662-7. doi: 10.1007/s12282-015-0621-z. Epub 2015 Jun 3. Breast Cancer. 2016. PMID: 26037335
1,986 results